General
Preferred name
ALVIMOPAN
Synonyms
Alvimopan (monohydrate) ()
ADL 8-2698 monohydrate ()
LY 246736 monohydrate ()
Alvimopan (ADL 8-2698) ()
ALVIMOPAN ANHYDROUS ()
Alvimopan (dihydrate) ()
ADL 8-2698 ()
LY 246736 ()
ADL 8-2698 dihydrate ()
LY 246736 dihydrate ()
LY 246736, ADL 8-2698 ()
Alvimopan monohydrate ()
Alvimopan dihydrate (LY246736 dihydrate) ()
ENTEREG ()
LY-246736 ()
LY-246736 DIHYDRATE ()
ALVIMOPAN DIHYDRATE ()
LY246736 ()
ADL-8-2698 ()
ANHYDROUS ALVIMOPAN ()
P&D ID
PD009306
CAS
170098-38-1
156053-89-3
1383577-62-5
Tags
available
drug
Approved by
FDA
First approval
2008
Drug indication
Constipation
Gastrointestinal disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible ¦Ì-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for ¦Ì-opioid receptor (Ki=0.47 nM) over ¦Ê- and ¦Ä-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus[1][2][3].
ABSORPTION Alvimopan's high affinity for the peripheral mu-receptor leads to slower absorption dependent on dissociation from the receptor and subsequently low oral bioavailability of less than 7%.
MOA Alvimopan competitively binds to mu-opioid receptor in the gastrointestinal tract but, unlike methylnaltrexone which relies upon it ionic charge, alvimopan owes its selectivity for peripheral receptors to its pharmacokinetics. Alvimopan binds to peripheral mu-receptors with a Ki of 0.2 ng/mL.
METABOLISM Alvimopan is primarily metabolized by intestinal flora to an active metabolite although it has no clinically significant contribution to the effects of the drug.
DESCRIPTION Alvimopan is a peripherally acting mu-opioid receptor antagonist , or PAMORA. (GtoPdb)
DESCRIPTION Alvimopan (ADL 8-2698) is a potent, selective, orally active and reversible ¦Ì-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan has selectivity for ¦Ì-opioid receptor (Ki=0.47 nM) over ¦Ê- and ¦Ä-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan can be used for the research of postoperative ileus[1][2][3].
PRICE 126
DESCRIPTION Alvimopan (LY 246736) is a synthetic trans-3, 4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons and the immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opioid-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone. (TargetMol Bioactive Compound Library)
DESCRIPTION The monohydrate salt form of Alvimopan could be commonly used in postoperative recovery of gastrointestinal for acting as a mu-opioid receptor (PAM-OR) antagonist with IC50: 1.7 nM. (BOC Sciences Bioactive Compounds)
Compound Sets
25
AdooQ Bioactive Compound Library
A11292
BOC Sciences Bioactive Compounds
alvimopan-monohydrate-cas-1383577-62-5-item-474535
Cayman Chemical Bioactives
23902
ChEMBL Approved Drugs
CHEMBL270190
ChEMBL Drugs
CHEMBL270190
Concise Guide to Pharmacology 2017/18
7471
Concise Guide to Pharmacology 2019/20
7471
Concise Guide to Pharmacology 2021/22
7471
Concise Guide to Pharmacology 2023/24
7471
Drug Repurposing Hub
DrugBank
DB06274
DrugBank Approved Drugs
DB06274
DrugCentral
143
DrugCentral Approved Drugs
143
DrugMAP
DMHR8KW
DrugMAP Approved Drugs
DMHR8KW
EUbOPEN Chemogenomics Library
EUB0000968
Guide to Pharmacology
7471
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL270190
MedChem Express Bioactive Compound Library
HY-76657A
HY-13243
NCATS Inxight Approved Drugs
Q153V49P3Z
ReFrame library
Selleckchem Bioactive Compound Library
alvimopan-dihydrate
alvimopan
TargetMol Bioactive Compound Library
T1242
VGSC-DB
NA0192
External IDs
63
Properties
(calculated by RDKit )
Molecular Weight
424.24
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
3.05
TPSA
89.87
Fraction CSP3
0.44
Chiral centers
3.0
Largest ring
6.0
QED
0.61
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Opioid Receptor
μ-opioid receptor
OPRD1, OPRK1, OPRM1
Pathway
GPCR/G protein
Neuronal Signaling
Endocrinology/Hormones
Neuroscience
Indication
postoperative ileus
MOA
Opioid Receptor antagonist
Therapeutic Class
Analgesics
VGSC Target
Nav1.5
Solubility
10 mM in DMSO
Recommended Cell Concentration
100 nM
Source data